- •Oral drugs benefit patients with EGFR+ and ALK+ positive advanced lung cancer.
- •Approximately 18% of EGFR+ and ALK+ positive patients do not receive oral drugs.
- •Patients diagnosed in later years were less likely to receive oral drugs.
- •Underuse of EGFR and ALK oral drugs is associated with inferior survival.
- •Oncology providers need to identify and address access barriers to oral drugs.
Materials and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med. 2009; 361: 947-957
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol. 2010; 11: 121-128
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med. 2010; 362: 2380-2388
- First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.J Clin Oncol. 2012; 30: 1122-1128
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol. 2013; 31: 3327-3334
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med. 2013; 368: 2385-2394
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.N Engl J Med. 2014; 371: 2167-2177
- NCCN Guidelines Insights: non-small cell lung cancer, version 5.2018.J Natl Compr Canc Netw. 2018; 16: 807-821
- Molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.J Oncol Pract. 2018; 14: 323-327
- Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.J Thorac Oncol. 2018; 13: 323-358
- Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities.Clin Lung Cancer. 2017; 18: 651-659
- Quality in the age of precision medicine: the clinician perspective.J Oncol Pract. 2016; 12: 839-843
- Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.Lancet. 2016; 388: 1002-1011
- Exploration of PCORnet data resources for assessing use of molecular-guided cancer treatment.JCO Clin Cancer Inform. 2020; 4: 724-735
- Precision Medicine in Oncology II: economics of targeted agents and immuno-oncology drugs.J Clin Oncol. 2020; 38: 351-358
- Specialty pharmacy services for patients receiving oral medications for solid tumors.Am J Health Syst Pharm. 2016; 73: 775-796
- Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.J Oncol Pharm Pract. 2018; 24: 424-432
- Use of charity financial assistance for novel oral anticancer agents.J Oncol Pract. 2018; 14: e221-e228
- Molecular testing turnaround time in non-small-cell lung cancer: monitoring a moving target.Clin Lung Cancer. 2018; 19: e589-e590
- Broad-based molecular testing for lung cancer: precisely the time for precision.JAMA. 2018; 320: 445-446
- Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.PLoS One. 2019; 14e0209709
- Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a Clinicogenomic database.JAMA. 2019; 321: 1391-1399
- Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.Lung Cancer. 2020; 143: 86-92
- Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer.JCO Clin Cancer Inform. 2019; 3: 1-10
- Characterizing potentially preventable cancer- and chronic disease-related emergency department use in the year after treatment initiation: a regional study.J Oncol Pract. 2018; 14: e176-e185
Fred Hutchinson Cancer Research Center. Cancer Surveillance System (CSS). Available at: https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/epidemiology/cancer-surveillance-system.html. Accessed on October 23, 2020.
- Validity of natural language processing for ascertainment of EGFR and ALK test results in seer cases of stage IV non-small-cell lung cancer.JCO Clin Cancer Inform. 2019; 3: 1-15
- A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.Ann Epidemiol. 2007; 17: 584-590
- Challenges of guarantee-time bias.J Clin Oncol. 2013; 31: 2963-2969
- Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database.Cancer Control. 2018; 251073274818789355
- Time-dependent covariates in the Cox proportional-hazards regression model.Annu Rev Public Health. 1999; 20: 145-157
- Statins associate with improved mortality among patients with certain histological subtypes of lung cancer.Lung Cancer. 2018; 126: 89-96
- Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy.Int J Radiat Oncol Biol Phys. 2012; 83: 1365-1373
- Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting.JAMA. 2018; 320: 469-477
- Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011.J Clin Oncol. 2015; 33: 2190-2196
- Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries.J Clin Oncol. 2017; 35: 2482-2489
- Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.Am J Manag Care. 2016; 22: 188-197
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.Am J Manag Care. 2016; 22: s78-s86
- Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014.JAMA Oncol. 2016; 2: 960-961
- Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019.JAMA. 2019; 321: 2025-2027
- Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.JAMA. 2014; 311: 1998-2006
- Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; 378: 113-125
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.Ann Oncol. 2020; 31: 1056-1064
- Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial.J Clin Oncol. 2020; 38: 3592-3603